Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Lamivudine plus interleukin-12 enhances immunity in Hep B

The most recent issue of Hepatology shows that the addition of interleukin-12 to lamivudine enhances T-cell reactivity to Hepatitis B virus, and interferon-gamma production.

News image

fiogf49gjkf04

Interleukin-12 is an immunomodulatory cytokine that promotes cellular immunity.

Pre-clinical data suggest that interleukin-12 inhibits Hepatitis B virus replication by stimulating interferon-gamma production.

Dr Nikolai Naoumov and colleagues from England investigated if a combination treatment will prolong suppression of Hep B replication.

The researchers assessed lamivudine plus recombinant human interleukin-12 in comparison with lamivudine monotherapy.

The research team included 15 patients with Hepatitis B e-antigent-positive and chronic Hepatitis B.

The patients were randomized to receive either lamivudine alone for 24 weeks in Group 1.

Interleukin-12 monotherapy does not abolish Hepatitis B replication
Hepatology

Group 2 included patients randomized to a combination of lamivudine for 16 weeks and recombinant human interleukin-12 ng/kg twice weekly.

The combination treatment started 4 weeks after initiation of lamivudine, and continued for 20 weeks.

In Group 3, the same schedule was followed as for group 2, only with lamivudine and a higher dose of recombinant human interleukin-12 of 500 ng/kg.

Serum Hepatitis B virus DNA levels, T-cell proliferation, frequency of virus-specific T-cells, and interferon-gamma production were evaluated.

The researchers evaluated these markers serially during and 24 weeks posttreatment.

The team found that lamivudine plus recombinant human interleukin-12 showed greater antiviral activity than lamivudine monotherapy.

However, after stopping lamivudine in Groups 2 and 3, serum Hepatitis B virus DNA increased significantly despite continued use of recombinant human interleukin-12.

Lamivudine plus recombinant human interleukin-12 treatment was associated with a greater increase in virus-specific T-cell reactivity, and interferon-gamma production.

The researchers noted an inverse correlation between the frequency of interferon-gamma producing CD4+ T-cells and viremia.

The research team observed that the T-cell proliferative response to Hepatitis B c-antigen did not differ between the 3 groups.

Dr Naoumov's team concludes, “The addition of interleukin-12 to lamivudine enhances T-cell reactivity to Hepatitis B virus and interferon-gamma production.”

“However, interleukin-12 does not abolish Hepatitis B replication in Hepatitis B e-antigen-positive patients.”

“It also does not maintain inhibition of Hepatitis B virus replication after lamivudine withdrawal.”

Hepatol 2005: 42(5): 1028-36
02 November 2005

Go to top of page Email this page Email this page to a colleague

 23 November 2017 
Distance travelling for rectal cancer outcomes
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us